Membership in the ITOG Corporate Leadership Council (CLC) provides a unique opportunity to strengthen communication and collaboration among industry partners and ITOG leadership, in direct support of our mission: “Catalyzing a Cure for Thyroid Cancer.”
Founded in 2003 by patient advocates and leading thyroid cancer experts, ITOG was created to address the urgent needs of patients facing complex diagnoses and limited treatment options. The founding vision was to build a “Dream Team” of world-renowned physicians and scientists across institutions and specialties, working collaboratively to accelerate progress and improve outcomes for patients.
Today, that vision continues through ITOG’s global network of physician-oncologists, endocrinologists, surgeons, pathologists, clinical trialists, and translational and basic science researchers dedicated to advancing thyroid cancer research and care.
A Platform for Meaningful Scientific Exchange
The ITOG CLC is designed not as a traditional sponsorship model, but as a platform for structured, bidirectional scientific engagement. Through the CLC, members gain:
CLC participation fosters transparent dialogue between industry and academic leadership, enabling alignment around innovation, trial development, patient accrual, and educational priorities.
Impact of ITOG Philanthropic Investment
ITOG strategically invests philanthropic support to fund and facilitate:
Principles of the ITOG Corporate Leadership Council
The ITOG CLC is guided by a shared commitment: do more for thyroid cancer patients by working together.
Activities & Engagement Opportunities
CLC membership includes:
Corporate Leadership Council Co-Chairs
Corporate Leadership Council Members
